EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Allosteric modulation of SHP2: Quest from known to unknown

Ning Wang iD, Shilin Zhu, Dan Lv, Yajun Wang, Muhammad B Khawar, Haibo Sun

Drug Development Research · 2023-11 · 84 (7) · 1395-1410

DOI: 10.1002/ddr.22100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 15.08.2023. Verfasst von Ning Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Src homology‐2 domain‐containing protein tyrosine phosphatase‐2 (SHP2) is a key regulatory factor in the cell cycle and its activating mutations play an important role in the development of various cancers, making it an important target for antitumor drugs. Due to the highly conserved amino acid sequence and positively charged nature of the active site of SHP2, it is difficult to discover inhibitors with high affinity for the catalytic site of SHP2 and sufficient cell permeability, making it considered an “undruggable” target. However, the discovery of allosteric regulation mechanisms provides new opportunities for transforming undruggable targets into druggable ones. Given the limitations of orthosteric inhibitors, SHP2 allosteric inhibitors have become a more selective and safer research direction. In this review, we elucidate the oncogenic mechanism of SHP2 and summarize the discovery methods of SHP2 allosteric inhibitors, providing new strategies for the design and improvement of SHP2 allosteric inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansProtein Tyrosine Phosphatase, Non-Receptor Type 11Amino Acid SequenceCell CycleEnzyme Inhibitors

Stichwörter der Autor:innen

SHP2's inhibitorsallosteric drugsallosteric regulationprotein tyrosine phosphatase

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
  • Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yangzhou, China.
  • Department of Oncology, Haian Hospital of Traditional Chinese Medicine, Haian, China.
  • School of Life Sciences, Anqing Normal University, Anqing, China.
  • Applied Molecular Biology and Biomedicine Lab, Department of Zoology, University of Narowal, Narowal, Pakistan.

ORCID-Profile: Ning Wang

Zitieren

APA

Wang, N., Zhu, S., Lv, D., Wang, Y., Khawar, M. B., & Sun, H. (2023). Allosteric modulation of SHP2: Quest from known to unknown. Drug Development Research, 84(7), 1395-1410. https://doi.org/10.1002/ddr.22100

Vancouver

Wang N, Zhu S, Lv D, Wang Y, Khawar MB, Sun H. Allosteric modulation of SHP2: Quest from known to unknown. Drug Development Research. 2023;84(7):1395-1410. doi:10.1002/ddr.22100

BibTeX
@article{Wang2023,
  author = {Wang, Ning and Zhu, Shilin and Lv, Dan and Wang, Yajun and Khawar, Muhammad B and Sun, Haibo},
  title = {Allosteric modulation of SHP2: Quest from known to unknown},
  journal = {Drug Development Research},
  year = {2023},
  volume = {84},
  number = {7},
  pages = {1395--1410},
  doi = {10.1002/ddr.22100}
}
Kostenlos starten →